Companies / Tyra Biosciences, Inc.
Tyra Biosciences, Inc.
Nasdaq: TYRACIK 1863127CARLSBAD, CA
Financials
Ownership
59.7M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 2.32% | 1,386,862 |
| Institutions | 100.97% | 60,254,418 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Todd HarrisCEOPresident and CEO · Director | 2.28% | 1,358,631 |
Bensen DanielFormerChief Discovery Officer | 0.25% | 146,981 |
Fuhrman AlanFormerChief Financial Officer | 0.06% | 36,164 |
Kaplan GillaDirector | 0.05% | 28,231 |
Kolchinsky PeterFormerDirector · 10% owner | — | — |
More Robert JDirector | — | — |
RA Capital Healthcare Fund LPFormerDirector · 10% owner | — | — |
RA Capital Management, L.P.FormerDirector · 10% owner | — | — |
RA Capital Nexus Fund, L.P.FormerDirector | — | — |
Shah Rajeev M.FormerDirector · 10% owner | — | — |
Institutional holders 142
View all →| Holder | Value | % of shares |
|---|---|---|
| $467.21M | 20.44% | |
| $148.87M | 6.52% | |
| $106.63M | 6.80% | |
| $100.52M | 6.41% | |
| $96.84M | 5.08% | |
| $88.73M | 5.66% | |
| $88.71M | 5.65% | |
| $76.19M | 4.86% | |
| $75.69M | 3.31% | |
| $68.36M | 3.59% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | State Street Corporation 13F manager | Add | — | $44.43M | +1.4M +185.59% | 2,140,368 3.59% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Add | — | $36.55M | +955K +32.54% | 3,890,589 6.52% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $30.20M | +946K +45.32% | 3,031,972 5.08% of shares | medium |
| Q4 2025 as of | Farallon Capital Management LLC 13F manager | Add | — | $24.27M | +923K +80.69% | 2,066,818 3.46% of shares | medium |
| Q1 2026 as of | Deerfield Management Company, L.P. 13F manager | New | — | $21.03M | +549K | 549,000 0.92% of shares | medium |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Trim | — | $-19.69M | -514K -72.22% | 197,748 0.33% of shares | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | Trim | — | $-17.88M | -467K -57.05% | 351,479 0.59% of shares | medium |
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | — | $16.00M | +1.1M | 1,143,818 1.92% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Farallon Capital Partners, L.P. | Passive13G | — |
| Todd Harris | Passive13G | — |
| Canaan XI L.P. | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| Farallon Capital Partners, L.P. | Passive13G/A | — |
| Janus Henderson Group PLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| TYRA | — | 90240B106 |